New Drug Shows Promise for Myelom... (em cell transplant to replace the many o...)

New Drug Shows Promise for Myeloma Patients

Date:5/9/2012

em cell transplant to replace the many of the cancerous plasma cells. However, many older patients are ineligible for this treatment.

The first study looked at lenalidomide treatment in people who weren't candidates for stem cell transplants, and it included just over 450 people over age 65 who had recently been diagnosed with multiple myeloma. One group received initial chemotherapy that included lenalidomide that was also followed by maintenance therapy with lenalidomide, while the second group just received the initial chemotherapy including lenalidomide. The final group received standard chemotherapy without lenalidomide.

After an average follow-up period of 30 months, the researchers found that the first group had an average progression-free survival of 31 months compared with just 14 months for the second group and only 13 months for the final group. This study wasn't designed to assess overall survival.

"This approach is approximately doubling the remission duration of old therapies from 15 to 30 months," said study author Dr. Antonio Palumbo, from the department of hematology at the University of Torino in Italy.

Palumbo said that cost always has to be considered in treatments. He said there are some cost savings associated with lenalidomide because it's an oral medication, not one that has to be given intravenously. In addition, if it prevents complications, such as bone fractures, it may help prevent hospitalization costs and disability.

The second study, conducted by researchers from Roswell Park Institute in New York, included 468 people younger than 71 years old who were undergoing stem cell transplants. Beginning 100 days after their transplants, half the group was given daily lenalidomide and the other half received placebo. Once the disease progressed, study participants were told which treatment they were receiving, and if they were on placebo, they were allowed to start taking lenalidomide.

At the time results
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress

Post Your Comments:

Related Image:

New Drug Shows Promise for Myeloma Patients

(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group are ... than 59,229 complaints since 2004 from women claiming they suffered ... as the Mirena IUD.* , Among the most common of ... where the IUD came out on its own. There are ... article. “Abdominal pain is also common, with 3,774 complaints. And ...

(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...

(Date:5/24/2013)... failed to replicate what appeared to be breakthrough results ... were published last year in the journal Science ... suggested that the drug bexarotene (marketed as Targretin) could ... a pathological hallmark of Alzheimer,s disease in ... the 2012 report, drug treatment quickly removed most of ...

(Date:5/24/2013)... Los Angeles, CA (PRWEB) May 24, 2013 ... is to present the 3rd Annual EB-5 Investment Summit: ... 2013. The Dealmakers Conference will focus on exploring alternative ... provide the latest market, legal and economic information, and ... legal professionals within the EB-5 industry. , "Our ...

(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...

Breaking Medicine News(10 mins):Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3 Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2 Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2 Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3 Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4

[0] Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] Multiple research teams unable to confirm high-profile Alzheimer's study [0] Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California [0] Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York

... self esteem, SAUSALITO, Calif., May 14 When Peggy ... afraid to go to school,because she had lost her hair ... of her custom-made hair pieces and invited her and her,mother ... -- and raised the money to pay for it., ...

... Room Temperature Stable Treatment for Hemophilia With ... Convenience to Patients, PRINCETON, N.J., May 13 ... and Drug Administration (FDA) has approved,NovoSeven(R) RT (Coagulation ... temperature stable recombinant product available,for the treatment of ...

... the unmet needs of ... and communities, SACRAMENTO, Calif., May 13 The ... for the use of,traditional and technologically advanced forms of ... nonprofit charities. Founding,organizations for this new alliance include Disabled ...

... Promoting ... Healthy Workplace, ... Health, a national non-profit organization of large employers, today,honored Data ... healthy workplace and encouraging a healthy,lifestyle for its employees and ...

... demonstrating ... time since separation; strategic investments ... - Management updates financial guidance based on year to date performance ... and operational momentum, BATESVILLE, Ind., May 13 Hill-Rom Holdings,Inc. (NYSE: HRC ), reporting for ...

... - Third quarter fiscal 2008 revenue of $21.9 million versus $23.8 million ... in the same quarter last year. ... ... Natural,Alternatives International, Inc. ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer and ...

Teen Girl Loses Hair But Gains Support FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors Charities Form Alliance to Preserve and Improve Charity Bingo National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year Natural Alternatives International, Inc. Announces Third Quarter Results

(Date:5/23/2013)... Mass. , May 23, 2013 Haemonetics Corporation (NYSE: ... Lindop , CFO & EVP-Business Development, will present at ... Conference in Boston, MA on May ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may access ... About Haemonetics Haemonetics (NYSE: ...

(Date:5/23/2013)... MGC Diagnostics Corporation (NASDAQ: MGCD ) ... scheduled a conference call to discuss its financial results ... April 30, 2013. The call will be at 4:30 ... will report financial results for the second quarter of ... May 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO ...

(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...

Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2 Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2

[0] Haemonetics to Present at The Deutsche Bank 38th Annual dbAccess Health Care Conference [0] MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 [0] Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support

... Oct. 28 Octapharma Group and Fresenius Kabi ... regarding the use of Fresenius Kabi,s HESylation® Technology ... the agreement, Fresenius Kabi will license its proprietary ... based on hydroxyethyl starch ("HES") which will be ...

... , MALVERN, Pa., Oct. 28 Featuring the lowest ... Siemens Healthcare,s SOMATOM® Definition Flash dual-source computed tomography (CT) ... for Children, Orlando, Fla., to better serve its pediatric ... of the radiation dose that systems previously required to ...

Cached Medicine Technology:Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2 Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3 Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 2 Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 3

Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children

This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...

... ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, ... 1-10 Inaccuracy (%) ... Imprecision(%) ... 0.1 Dimensions: ...

... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...

This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 2-20 microliter range....

Medicine Products:

Corning Lambda Single Channel Pipettor, 0.5-10 ul Variable Volume Pipette H10 Pipetman Ultra U10 Micropipet, adjustable volume, 2-20 microliter